Camlin Fine Q1FY27: consolidated loss widens to ₹33.6 Cr as EBITDA margin falls to 3.4%
PAT -214.8% YoY · revenue +22.7% · margins compressing
₹519.88 Cr
+22.7% YoY
₹-33.62 Cr
-214.8% YoY
-6.45%
-4pp YoY
₹-1.65
Camlin Fine Sciences' consolidated (primary) Q1 FY27 loss widened to ₹33.62 Cr from ₹10.68 Cr a year ago — reported PAT down roughly 215% YoY; adjusted for this quarter's ₹11.11 Cr exceptional charge, the underlying loss was still up ~111% YoY to ₹22.51 Cr. Standalone lost a smaller ₹12.31 Cr, more than 2x divergence from consolidated — the gap is mostly subsidiaries' operating losses, the exceptional charge (booked only at the consolidated level) and a ₹1.83 Cr discontinued-operations loss that doesn't touch the standalone P&L. Consolidated revenue from operations was ₹519.88 Cr, up 22.7% YoY (against our tracked year-ago base of ₹423.55 Cr) and 22.4% QoQ against this filing's own recast Q4 FY26 column of ₹424.81 Cr. No management press release accompanied this filing, and there is no formal quarterly Street consensus available for Camlin Fine, so vs-Street reads unknown — Trendlyne's two-analyst FY27 consensus pegs full-year revenue near ₹2,361 Cr and EPS at ₹7.65, both now resting on a much bigger back-half recovery after this loss-making Q1.
Q1 FY-2027 vs prior quarters
The loss was a margin story, not a revenue miss. Consolidated operating EBITDA (segment results before exceptional items) fell to ₹17.64 Cr — a 3.39% margin — from ₹21.19 Cr (4.99%) in Q4 FY26 and ₹20.29 Cr (4.98%) in Q1 FY26, even as revenue grew double digits both sequentially and YoY, meaning input and employee costs outpaced the topline. The ₹11.11 Cr exceptional charge splits into a ₹10.88 Cr shortfall on the insurance claim settlement for the February 2026 fire at CFS Do Brasil's blending unit (Note 7) plus ₹0.23 Cr unallocated — a real cash item, not a paper adjustment. By segment: Specialty Ingredients (the largest) grew revenue 36.7% YoY to ₹401.32 Cr but its segment result fell 15.1% YoY to ₹25.47 Cr; Aroma revenue rose 36.6% YoY to ₹77.41 Cr — consistent with management's guided vanillin volume/realisation pickup — yet stayed loss-making at -₹3.38 Cr, though narrower than Q4's -₹8.80 Cr; Performance Chemicals & Others swung from a ₹3.65 Cr profit in Q4 to a -₹4.44 Cr loss, still better than the -₹7.65 Cr loss a year ago.
The stock went into the print at ₹126, down 0.1% over the past month of trading.
For context: revenue is at a 6-quarter high.
Management anticipates improved realizations and increased volumes for vanillin in upcoming quarters, driven by reduced tariffs and increased ethyl vanillin production. The Blends business is projected for strong growth, aiming for INR1,400 crores in FY27. While acknowledging near-term challenges from geopolitical conf
— This quarter: missed
Against the FY27 guidance from the May 2026 call — revenue of ₹2,200-2,400 Cr and EBITDA margins of 12-14% — this quarter's 3.39% margin is a sharp miss, and the ₹519.88 Cr Q1 run-rate needs to keep accelerating to reach the guided revenue band; the ₹1,400 Cr FY27 Blends target (within Specialty Ingredients) can't be verified from this filing's segment cuts. Two corporate developments this quarter: the Company completed its open offer for Vinpai S.A. minority shareholders on July 6, 2026, lifting its stake to 95.41% from 83.82% for ₹19.46 Cr; and the Board held the 33rd AGM and filed the FY26 BRSR report alongside these results. Management separately noted a second fire (Dahej Diphenol unit, May 23, 2026) is expected to be fully insurance-covered with no residual loss (Note 9) — worth checking given the ₹10.88 Cr shortfall just booked on the earlier Brazil claim. This sets up a Q2 FY27 where the key questions are whether Aroma's revenue growth converts to segment profit and whether the EBITDA margin starts closing the gap to the 12-14% guided range.
W1
Aroma segment breakeven — revenue up 36.6% YoY on management's guided vanillin volume/realisation improvement, but the segment still lost ₹3.38 Cr this quarter.
W2
EBITDA margin trajectory toward the guided 12-14% FY27 range from just 3.39% in Q1FY27.
W3
Insurance recovery on the May-2026 Dahej Diphenol fire (Note 9, management expects full coverage) versus the ₹10.88 Cr shortfall already booked on the Brazil fire claim (Note 7).
Rs. in Million in source, ÷10 to Cr. Consolidated PBT−tax (-31.80 Cr) ties to continuing-ops PAT; total PAT (-33.62 Cr) additionally nets a -1.83 Cr discontinued-ops loss (CFS Europe SpA liquidation + CFS Wanglong Ningbo wind-down). DB year-ago revenue (₹423.55 Cr) is pre-restatement; PDF's own recast Q1FY26 column shows ₹407.72 Cr. DB's stored previous-quarter comparator was standalone-only, so QoQ used this filing's own consolidated Q4FY26 column (₹424.81 Cr) instead.
Revenue growth masks net loss shock — vanillin ramp and cost inflation test credibility
Q1 revenue surged 23% YoY to ₹520 Cr, but the company swung to a ₹34 Cr net loss. Geopolitical raw material inflation (4-5% margin hit), financing drag, and a vanillin plant running at 26% capacity are the culprits. Management's Q3 margin recovery claims now rest on execution largely outside its control.
₹-33.6 Cr
-215% YoY
₹519.9 Cr
+22.7% YoY, +183% QoQ
-6.5%
vs. +1-2% expected
26%
560 tons on 1,500 capacity
Where the loss came from
The ₹34 Cr net loss is not a one-time blip—it's the sum of structural pressures management did not foresee when guiding in prior quarters. Revenue growth of 23% masks a complete margin collapse. The company's own segment-level EBITDA (Specialty Ingredients 6.35%, Aroma -₹3–4.5 Cr, Performance 2.5%) doesn't reconcile to a ₹34 Cr consolidated loss, but the call itemizes the gap: raw material inflation dragged gross margins down 4-5%, financing costs added another 1-1.5% hit, a Brazil fire cost ₹8 Cr, and the vanillin plant running at 26% utilization burned ₹3–4.5 Cr in fixed-cost absorption. Together, these turn what should have been a ₹30–40 Cr EBITDA quarter (at ~6-7% margin) into a net loss.
Claims vs. what holds up
Revenue +28% YoY; very strong top-line execution
OverstatedActual +22.7% YoY (not 28%). Overstated by 5 points.
Margins at 4% EBITDA; elevated from prior 45% due to raw material pressure
ContradictedCompany posted ₹-33.6 Cr net loss (NPM -6.5%). Segment-level positive claims don't reconcile to consolidated result.
Q3 will deliver double-digit EBITDA margins; FY27 average 10-11%
OverstatedQ1 negative, Q2 guided 'slightly better'. Math for 10-11% full-year average requires Q3-Q4 avg 13-15%+. Ambitious given vanillin ramp risks.
Vanillin production 3,600–4,000 tons FY27 (prior guidance)
MissedCut to ~3,000 tons. 4 campaign switches eat 1 month each; ethyl vanillin ramp slower for quality. Miss of 600–1,000 tons.
What changed on this call
FY27 revenue guidance cut from ₹2,400 Cr to ₹2,200–2,300 Cr (miss of ₹100–200 Cr)
Vanillin production target revised down to ~3,000 tons from prior 3,600–4,000 (600–1,000 ton shortfall)
Margin recovery pushed to Q3; Q2 expected only 'slightly better' than Q1
Diphenol plant restart deferred to Q3 with no firm timeline; asset utilization clarity pending
Vanillin EBITDA expectation revised: Q2-Q3 profitability contingent on methyl vanillin ramp (cost reduction play, not volume)
How the street is positioned
The market's verdict is clear: stock down 43.6% from its all-time high of ₹202.45, now trading at ₹114.11 below all major moving averages (SMA20 ₹122.63, SMA50 ₹128.39, SMA200 ₹139.15). The post-result price action confirmed the bearish read: day-1 decline of -13.99% (delivery 51.1%, indicating heavy institutional selling), widening to day-3 loss of -17.14%. This tells you the street is not buying the "near-term headwinds" narrative.
Institutional flows are negative. FII ownership fell to 0.91% (from 0.94% prior quarter); DII ownership fell sharply to 5.42% (from 7.70%)—a 2.28 percentage-point quarterly decline. Both sets of institutions are trimming, not adding. Promoter ownership stable at 48.03%. Bulk/block activity (JUNOMONETA buy/sell near ₹119.80–119.87) is neutral churn, not a signal. The street is pricing in longer-term margin pressure and lower earnings power than management is admitting.
The honest read: This is neither a recovery story nor a distressed-asset play—it's a Hold. Camlin has real structural drivers (blends momentum, vanillin opportunity, antidumping support), but near-term execution is uncertain and margins are more fragile than management is publicly admitting. The street is right to be cautious; a 43% drawdown from ATH reflects genuine earnings pressure, not a valuation opportunity yet.
Risks, ranked by how much they should concern a holder
Margin sustainability under geopolitical cost inflation
HighRaw material costs (4-5% margin drag) and freight are unhedged; management assumes stabilization by Q2-Q3 with no visibility. If conflict persists 6+ months, margin recovery targets (Q3 double-digit EBITDA) miss. No cost pass-through possible without losing customers.
Vanillin ramp execution and fixed-cost absorption
High26% capacity utilization (560 tons on 1,500 capacity) is unsustainable. Fixed cost ₹7 Cr/month = ₹3–4.5 Cr EBITDA loss/qtr at current run. Break-even requires 70%+ (1,000+ tons/qtr). Campaign switching delays (4 per year, 1 month each) slow ramp. If utilization doesn't reach 70% by Q3, vanillin becomes a multi-year drag, not a near-term profit engine.
Working capital crisis and liquidity pressure
HighRed Sea rerouting via South Africa has extended working capital cycle (100 days now, likely longer). ₹100–200 Cr credit draw planned by year-end. If credit lines are unavailable or costlier than budgeted, dealer financing costs escalate further, compressing margins further.
Vanillin pricing power capped by Solvay and multinational buyer leverage
MediumDespite 5,000–6,000 ton US/Europe supply gap, pricing is stuck at $13–14/kg. Solvay's $18 asking price is deterring customer migration; multinational customers resist disparate global pricing, preventing Camlin from capturing the full supply premium. Chinese producers at $7–8 + 250% duty ($20 effective) remain a shadow price cap.
Segment profitability reconciliation and earnings quality
MediumSpecialty Ingredients 6.35% EBITDA, Aroma -₹3–4.5 Cr, Performance 2.5% should sum to ~₹0–10 Cr EBITDA gross, but consolidated result is ₹-34 Cr net loss. Brazil fire (₹8 Cr), finance costs, and intersegment eliminations account for the gap, but full transparency is lacking. If exceptional items prove recurring, earnings quality deteriorates.
Diphenol plant restart failure or alternative use delay
Low-MediumPlant shutdown 9+ months with no firm restart date. Q3 decision promised but capital remains stranded. If restart is not economic (Chinese intermediates now cheaper) and alternative product ramp fails, the asset is a permanent loss. Opportunity cost is capital tied up that could fund vanillin or blends capex.
What to watch next
1 · Q2 margin recovery: organic EBITDA vs. Q1 loss
The critical test. If Q2 EBITDA is positive (target ₹20–30 Cr at 3.5–5% margin), the Q3 double-digit target becomes credible. If Q2 is still weak or losses continue, guidance for 10-11% FY27 margin is at risk of another cut. Watch gross margin (target 14-15% ex-geo headwinds) and vanillin contribution (target -₹1–2 Cr, improving from -₹3–4.5 Cr in Q1).
2 · Vanillin utilization ramp: from 26% (560 tons) to 50%+ (750+ tons)
Each 10-point rise in capacity utilization saves ₹1–1.5 Cr in quarterly EBITDA. Q2 should show production of 700–800 tons; if it's still <600 tons, the ramp has stalled. Watch for methyl vanillin campaign switch success (should be lower-cost, higher-margin than ethyl) and customer order shipments from F&F pipeline.
3 · Geopolitical cost normalization: raw material price and freight trend
Management assumes 3-month stabilization from Q1; if war persists, raw material costs stay elevated. Watch CFO commentary on pass-through to customers (50% cost pass guidance is aggressive) and any commentary on hedging or forward contracting. If raw material prices are still rising in Q2, margin recovery doesn't happen.
4 · Diphenol plant decision clarity (Q3 promised)
Asset sitting idle for 9+ months is not credible. Management must commit to restart (with timeline) or alternative product ramp (with capex estimate and revenue ramp). If deferred again to Q4, the credibility hit will be material.
The number to track from here
Organic EBITDA margin (stripping out exceptional items and financing costs). The Q1 headline loss was ₹34 Cr, but the company's organic EBITDA (before Brazil fire, finance costs, and intersegment eliminations) was likely ₹0–10 Cr—a 0–2% margin. Management is guiding for 10-11% full-year EBITDA margin (₹220–253 Cr on ₹2,200–2,300 Cr revenue). For that to hold, Q2-Q4 must average 11-13% margin. That's a steep recovery from a 0-2% Q1 base, contingent on geopolitical stabilization (not guaranteed) and vanillin ramp (not yet proven). If Q2 organic EBITDA is <5% margin, the 10-11% full-year target is effectively dead and guidance will need another cut. That's the test.
Camlin Fine Sciences is neither a buy on strength nor a value trap at 43% down from ATH. The company has real structural tailwinds—blends momentum and vanillin opportunity—but near-term execution is clouded by geopolitical cost inflation, working capital stress, and a vanillin plant running at unsustainable 26% capacity utilization. Management's revised guidance (FY27 ₹2,200–2,300 Cr, 10-11% EBITDA margin) requires Q3-Q4 to deliver double-digit margins after Q1's loss and Q2 weakness; that math is aggressive given unresolved raw material pressures and pricing power capped by Solvay's global customer leverage.
The Q2 result is the gate. Evidence that margins are recovering (to 5%+) and vanillin capacity is ramping (to 50%+ utilization) would restore some credibility. Without it, the downside risk is material—lower guidance cuts, potential dividend cut, and further multiple compression. Institutions are already exiting (FII/DII trimming QoQ); if they see Q2 miss the margin recovery target, the selling could accelerate.
Rating: Hold. Price target: ₹105–115 (downside to fair value of 10-11x FY28 EBITDA if margins normalize to 10%+; upside to ₹130–140 only if geopolitical stabilization + vanillin ramp both deliver by H2 FY27). Watch the Q2 organic EBITDA margin; it's the clearest signal of whether management's guidance is credible or the third cut is coming.